Simple blood test could spare prostate cancer patients from unnecessary scans
NCT ID NCT07553754
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to develop a blood test that detects RNA from tiny particles (exosomes) to predict if prostate cancer has spread to the bones. Researchers will analyze blood samples from 1,000 men with newly diagnosed prostate cancer and compare results with PSMA PET scans. The goal is to create a test that can reliably rule out bone metastasis, potentially reducing the need for expensive imaging in low-risk patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Plasma exosomal RNA signature (liquid biopsy test)
What this could lead to
If successful, this blood test could safely rule out bone metastasis in low-risk prostate cancer patients, avoiding unnecessary PSMA PET scans and reducing healthcare costs.
What could go wrong
This is an early-phase diagnostic study with a target specificity of only 30%, meaning many patients may still need imaging. The test is not yet validated for routine clinical use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSMA-PET are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Yan'an University
RECRUITINGYan’an, Shaanxi, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
General Hospital of Ningxia Medical University
RECRUITINGYinchuan, Ningxia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Qinghai University Affiliated Hospital
RECRUITINGXining, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shaanxi Provincial People's Hospital
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Hospital of Lanzhou University
RECRUITINGLanzhou, Gansu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
RECRUITINGXianyang, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Weinan Central Hospital
RECRUITINGWeinan, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xijing 986 Hospital
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xijing Hospital
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact